College of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, Pocheon, Gyeonggi-do, 11160, Republic of Korea.
College of Pharmacy, Woosuk University, Wanju-gun, Jeollabuk-do, 55338, Republic of Korea.
Neurotherapeutics. 2022 Jul;19(4):1298-1312. doi: 10.1007/s13311-022-01244-5. Epub 2022 May 25.
Adult neurogenesis, a process controlling the proliferation to maturation of newly generated neurons in the post-developmental brain, is associated with various brain functions and pathogenesis of neuropsychological diseases, such as Parkinson's disease (PD) and depression. Because orphan nuclear receptor estrogen-related receptor γ (ERRγ) plays a role in the differentiation of neuronal cells, we investigated whether an ERRγ ligand enhances adult neurogenesis and regulates depressive behavior in a LRRK2-G2019S-associated mouse model of PD. Young female LRRK2-G2019S mice (7-9 weeks old) showed depression-like behavior without dopaminergic neuronal loss in the nigrostriatal pathway nor motor dysfunction. A significant decrease in adult hippocampal neurogenesis was detected in young female LRRK2-G2019S mice, but not in comparable male mice. A synthetic ERRγ ligand, (E)-4-hydroxy-N'-(4-(phenylethynyl)benzylidene)benzohydrazide (HPB2), ameliorated depression-like behavior in young female LRRK2-G2019S mice and enhanced neurogenesis in the hippocampus, as evidenced by increases in the number of bromodeoxyuridine/neuronal nuclei-positive cells and in the intensity and number of doublecortin-positive cells in the hippocampal dentate gyrus (DG). Moreover, HPB2 significantly increased the number of spines and the number and length of dendrites in the DG of young female LRRK2-G2019S mice. Furthermore, HPB2 upregulated brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB) signaling, one of the important factors regulating neurogenesis, as well as phosphorylated cAMP-response element binding protein-positive cells in the DG of young female LRRK2-G2019S mice. Together, these results suggest ERRγ as a novel therapeutic target for PD-associated depression by modulating adult neurogenesis and BDNF/TrkB signaling.
成人神经发生,即控制发育后大脑中新生成神经元增殖和成熟的过程,与各种大脑功能和神经心理疾病的发病机制有关,如帕金森病 (PD) 和抑郁症。由于孤儿核受体雌激素相关受体γ (ERRγ) 在神经元细胞的分化中发挥作用,我们研究了 ERRγ 配体是否能增强成年神经发生并调节 LRRK2-G2019S 相关 PD 小鼠模型中的抑郁行为。年轻雌性 LRRK2-G2019S 小鼠 (7-9 周龄) 表现出抑郁样行为,但黑质纹状体通路中多巴胺能神经元缺失和运动功能障碍。年轻雌性 LRRK2-G2019S 小鼠的成年海马神经发生显著减少,但在可比的雄性小鼠中没有减少。一种合成的 ERRγ 配体,(E)-4-羟基-N'-(4-(苯乙炔基)苯甲酰基)苯甲脒 (HPB2),改善了年轻雌性 LRRK2-G2019S 小鼠的抑郁样行为,并增强了海马神经发生,表现为溴脱氧尿苷/神经元核阳性细胞数量增加,以及海马齿状回 (DG) 中双皮质素阳性细胞的强度和数量增加。此外,HPB2 还显著增加了年轻雌性 LRRK2-G2019S 小鼠 DG 中的棘突数量以及树突的数量和长度。此外,HPB2 上调了脑源性神经营养因子 (BDNF)/原肌球蛋白受体激酶 B (TrkB) 信号通路,这是调节神经发生的重要因素之一,以及年轻雌性 LRRK2-G2019S 小鼠 DG 中磷酸化 cAMP 反应元件结合蛋白阳性细胞的数量。综上所述,这些结果表明 ERRγ 可通过调节成年神经发生和 BDNF/TrkB 信号通路成为治疗 PD 相关抑郁症的新靶点。